A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei

British Journal of Cancer

Volumn 99, Issue 4, 2008, Pages 591-596

  Farquharson, A L ^a   Pranesh, N ^a   Witham, G ^a   Swindell, R ^a   Taylor, M B ^a   Renehan, A G ^a,b   Rout, S ^a   Wilson, M S ^a   O'Dwyer, S T ^a   Saunders, M P ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Capecitabine; Chemotherapy; Mitomycin C; Pseudomyxoma peritonei

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; MITOMYCIN C; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE REDUCTION; DRUG USE; FEMALE; HAND FOOT SYNDROME; HEALTH CENTER; HEALTH STATUS; HUMAN; HUMAN TISSUE; LETHARGY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PERITONEUM PSEUDOMYXOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; VOMITING;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 49549099266     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604522     Document Type: Article

References (30)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
2. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M (2007) Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 14: 2300-2308
3. Bibi R, Pranesh N, Saunders MP, Wilson MS, O' Dwyer S T, Stern PL, Renehan AG (2006) A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer 95: 1258-1264
4. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349-358
5. Crooke ST, Bradner WT (1976) Mitomycin C: a review. Cancer Treat Rev 3: 121-139
6. Halila H, Stenman UH, Seppala M (1986) Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 57: 1327-1329
7. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292
8. Levitz JS, Sugarbaker PH, Lichtman SM, Brun EA (2004) Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: response to capecitabine. J Clin Oncol 22: 1518-1520
9. Moran BJ (2006) Establishment of a peritoneal malignancy treatment centre in the United Kingdom. Eur J Surg Oncol 32: 614-618
10. Murphy EM, Sexton R, Moran BJ (2007) Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 50: 37-42
11. NCI (2004) National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0., http://www.safetyprofiler-ctep.nci.nih.gov/CTC/ CTC.aspx (accessed 27 April 2008)
12. Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17: 857-872
13. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M (1988) Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 21: 185-190
14. Padhani AR, Ollivier L (2001) The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 74: 983-986
15. Pranesh N, Menasce LP, Wilson MS, O'Dwyer ST (2005) Pseudomyxoma peritonei: unusual origin from an ovarian mature cystic teratoma. J Clin Pathol 58: 1115-1117
16. Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P (2004) Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 91: 839-843
17. Renehan AG, O'Dwyer ST, Stern PL (2008) Pseudomyxoma peritonei In Cancer Encyclopedia, Schwab M (ed). London: Spinger
18. Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ (1997) Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 2: 197-226
19. Rout S, Renehan AG, Parkinson M, Saunders MP, Fulford PE, Wilson MS, O' Dwyer ST (2008) The treatments and outcomes of peritoneal tumours through a centralised national service (UK). Dis Colon Rectum (in press)
20. Saunders M, Iveson T (2006) Management of advanced colorectal cancer: state of the art. Br J Cancer 95: 131-138
21. Sjovall K, Nilsson B, Einhorn N (2002) The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 85: 175-178
22. Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94: 1408-1414
23. Sprangers MA, te Velde A, Aaronson NK (1999) The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on quality of life. Eur J Cancer 35: 238-247
24. Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7: 69-76
25. Sugarbaker PH, Chang D (1999) Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 6: 727-731
26. Sulkin TV, O'Neill H, Amin AI, Moran B (2002) CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol 57: 608-613
27. Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, Erten O (2002) Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 85: 108-113
28. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106
29. van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA (2002) Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 9: 961-967
30. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA (2001) Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 88: 458-463